Zhou AY - Search Results

1

ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.

Akinjiyan FA, Nassief G, Phillipps J, Adeyelu T, Elliott A, Abdulla F, Zhou AY, Souroullas G, Kim KB, Vanderwalde A, Park SJ, Ansstas G. Akinjiyan FA, et al. Among authors: zhou ay. Sci Rep. 2024 Feb 11;14(1):3444. doi: 10.1038/s41598-024-54136-3. Sci Rep. 2024. PMID: 38341515 Free PMC article.

2

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios.

Khaddour K, Zhou A, Butt OH, Budde G, Malashevich AK, Ansstas G. Khaddour K, et al. Front Oncol. 2022 Nov 17;12:978996. doi: 10.3389/fonc.2022.978996. eCollection 2022. Front Oncol. 2022. PMID: 36465349 Free PMC article.

3

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity.

Zhou A, Butt O, Ansstas M, Mauer E, Khaddour K, Ansstas G. Zhou A, et al. J Natl Compr Canc Netw. 2023 Jul;21(7):688-693.e3. doi: 10.6004/jnccn.2022.7102. J Natl Compr Canc Netw. 2023. PMID: 37433433

4

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.

Akinjiyan FA, Morecroft R, Phillipps J, Adeyelu T, Elliott A, Park SJ, Butt OH, Zhou AY, Ansstas G. Akinjiyan FA, et al. Among authors: zhou ay. Int J Mol Sci. 2023 Jun 28;24(13):10771. doi: 10.3390/ijms241310771. Int J Mol Sci. 2023. PMID: 37445949 Free PMC article. Review.

5

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.

Strelnikov J, Zhou A, Butt O, Ansstas M, Ansstas G. Strelnikov J, et al. J Natl Compr Canc Netw. 2023 Aug 29;21(10):991-999. doi: 10.6004/jnccn.2023.7032. J Natl Compr Canc Netw. 2023. PMID: 37647938

6

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma.

Khaddour K, Zhou A, Butt O, Huang J, Ansstas G. Khaddour K, et al. Front Oncol. 2023 Sep 20;13:1276729. doi: 10.3389/fonc.2023.1276729. eCollection 2023. Front Oncol. 2023. PMID: 37799464 Free PMC article.

7

PARP inhibition and immunotherapy: a promising duo in fighting cancer.

Phillipps J, Zhou AY, Butt OH, Ansstas G. Phillipps J, et al. Among authors: zhou ay. Transl Cancer Res. 2023 Sep 30;12(9):2433-2437. doi: 10.21037/tcr-23-726. Epub 2023 Aug 3. Transl Cancer Res. 2023. PMID: 37859734 Free PMC article. No abstract available.

8

Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification.

Nassief G, Butt OH, Zhou AY, Ansstas G. Nassief G, et al. Among authors: zhou ay. JAAD Case Rep. 2024 Apr 16;48:59-61. doi: 10.1016/j.jdcr.2024.04.005. eCollection 2024 Jun. JAAD Case Rep. 2024. PMID: 38778889 Free PMC article. No abstract available.

9

Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma.

Morecroft R, Phillipps J, Zhou A, Butt O, Khaddour K, Johanns T, Ansstas G. Morecroft R, et al. Front Oncol. 2024 May 8;14:1385094. doi: 10.3389/fonc.2024.1385094. eCollection 2024. Front Oncol. 2024. PMID: 38779101 Free PMC article.

10

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma.

Phillipps J, Nassief G, Morecroft R, Adeyelu T, Elliott A, Abdulla F, Vanderwalde A, Park S, Butt O, Zhou A, Ansstas G. Phillipps J, et al. NPJ Precis Oncol. 2024 Sep 5;8(1):187. doi: 10.1038/s41698-024-00684-w. NPJ Precis Oncol. 2024. PMID: 39232122 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters